Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)
August 23, 2021 10:18 AM EDTUpdated 10:36 AM
FDA+
Coronavirus

Pfiz­er earns long-await­ed full FDA nod for Covid-19 vac­cine, a hope­ful aid in US cam­paign

Kyle Blankenship

The FDA on Mon­day an­nounced its full ap­proval for Pfiz­er and BioN­Tech’s mR­NA-based Covid-19 vac­cine for in­di­vid­u­als 16 and old­er, po­ten­tial­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times